Multiplicity corrections in life sciences: challenges and consequences

Otília Menyhárt^{1

2

3}, Balázs Győrffy^{1

3

4}

Affiliations

¹ Department of Bioinformatics, Semmelweis University, H-1094 Budapest, Hungary.
² Cancer Biomarker Research Group, Institute of Molecular Life Sciences, Research Centre for Natural Sciences, H-1117 Budapest, Hungary.
³ National Laboratory for Drug Research and Development, Research Centre for Natural Sciences, H-1117 Budapest, Hungary.
⁴ Department of Biophysics, Medical School, University of Pecs, H-7624 Pecs, Hungary.

Otília Menyhárt et al. Int J Epidemiol. 2025.

. 2025 Jun 11;54(4):dyaf098.

doi: 10.1093/ije/dyaf098.

Otília Menyhárt^{1

2

3}, Balázs Győrffy^{1

3

4}

¹ Department of Bioinformatics, Semmelweis University, H-1094 Budapest, Hungary.
² Cancer Biomarker Research Group, Institute of Molecular Life Sciences, Research Centre for Natural Sciences, H-1117 Budapest, Hungary.
³ National Laboratory for Drug Research and Development, Research Centre for Natural Sciences, H-1117 Budapest, Hungary.
⁴ Department of Biophysics, Medical School, University of Pecs, H-7624 Pecs, Hungary.

No abstract available

References

1. Ioannidis JP. Contradicted and initially stronger effects in highly cited clinical research. JAMA 2005;294:218–28. - PubMed
1. Neher A. Probability pyramiding, research error and the need for independent replication. Psychol Rec 1967;17:257–62.
1. Begley CG, Ellis LM. Raise standards for preclinical cancer research. Nature 2012;483:531–3. - PubMed
1. Errington TM, Mathur M, Soderberg CK et al. Investigating the replicability of preclinical cancer biology.eLife 2021;10:e71601. - PMC - PubMed
1. Jager LR, Leek JT. An estimate of the science-wise false discovery rate and application to the top medical literature. Biostatistics 2014;15:1–12. - PubMed